Add time:07/20/2019         Source:sciencedirect.com

In continuation of our efforts toward identification and optimization of novel non-nucleoside reverse transcriptase inhibitors (NNRTIs), we have employed a structure-based bioisosterism strategy, with which a new series of diarylpyridazine (DAPD) derivatives were synthesized and evaluated for their anti-HIV-1 (human immunodeficiency virus type 1) activity. Most of the title compounds displayed excellent anti-HIV-1 activity at submicromolar concentrations ranging from 34 nM to 5.08 μM. The most promising compound 8g inhibited HIV-1 IIIB in MT-4 cells at a low EC50 value (0.034 μM), which was lower than the reference drug nevirapine and delavirdine. The structure activity relationships (SARs) were discussed and rationalized by docking simulations.

We also recommend Trading Suppliers and Manufacturers of 4,5-DIBROMO-2-PHENYL-2,3-DIHYDROPYRIDAZIN-3-ONE (cas 14305-08-9). Pls Click Website Link as below: cas 14305-08-9 suppliers